ProCE Banner Activity

Avelumab: A New Treatment Paradigm for Metastatic Merkel Cell Carcinoma

Clinical Thought
In this commentary, Howard L. Kaufman, MD, highlights practice-changing clinical trial results on avelumab, the first FDA-approved treatment for metastatic Merkel cell carcinoma.

Released: May 19, 2017

Expiration: May 18, 2018

No longer available for credit.

Share

Faculty

Howard L. Kaufman

Howard L. Kaufman, MD

Associate Director for Clinical Sciences
Chief Surgical Officer

Department of Surgical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck KGaA

Pfizer, Inc.

Faculty Disclosure

Primary Author

Howard L. Kaufman, MD

Associate Director for Clinical Sciences
Chief Surgical Officer

Department of Surgical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Howard L. Kaufman, MD, has disclosed that he has received consulting fees from Amgen, Celldex, EMD Serono, Merck, Prometheus, and Turnstone Biologics and funds for research support from Amgen and Merck.